European Journal of Medicinal Chemistry Reports

metrics 2024

Advancing medicinal chemistry through open access innovation.

Introduction

European Journal of Medicinal Chemistry Reports, published by ELSEVIER, is a vital platform dedicated to advancing the field of medicinal chemistry through open access communication of high-quality research. With an impact factor reflecting its growing influence, this journal has rapidly established a reputation for scholarly excellence since its launch in 2021. It serves as a converging point for innovative studies and reviews that span the disciplines of chemistry and molecular medicine, reflected in its Q2 and Q3 quartile rankings in relevant categories for 2023. Situated in France, the journal is accessible globally, ensuring that researchers, professionals, and students can easily engage with significant findings and methodologies in medicinal chemistry. The open access model facilitates the dissemination of knowledge, bridging gaps between laboratory research and practical applications in drug development. By fostering collaboration and highlighting emerging trends, the European Journal of Medicinal Chemistry Reports plays a crucial role in shaping the future of therapeutic innovations.

Metrics 2024

SCIMAGO Journal Rank0.59
Journal Impact Factor4.00
Journal Impact Factor (5 years)4.00
H-Index11
Journal IF Without Self4.00
Eigen Factor0.00
Normal Eigen Factor0.10
Influence0.62
Immediacy Index0.50
Cited Half Life1.60
Citing Half Life7.00
JCI0.94
Total Documents108
WOS Total Citations363
SCIMAGO Total Citations432
SCIMAGO SELF Citations2
Scopus Journal Rank0.59
Cites / Document (2 Years)4.27
Cites / Document (3 Years)4.27
Cites / Document (4 Years)4.27

Metrics History

Rank 2024

Scopus

Chemistry (miscellaneous) in Chemistry
Rank #43/111
Percentile 61.26
Quartile Q2
Molecular Medicine in Biochemistry, Genetics and Molecular Biology
Rank #115/178
Percentile 35.39
Quartile Q3

IF (Web Of Science)

CHEMISTRY, MEDICINAL
Rank 24/72
Percentile 67.40
Quartile Q2

JCI (Web Of Science)

CHEMISTRY, MEDICINAL
Rank 25/72
Percentile 65.28
Quartile Q2

Quartile History

Similar Journals

CURRENT TOPICS IN MEDICINAL CHEMISTRY

Leading the Way in Medicinal Chemistry Research
Publisher: BENTHAM SCIENCE PUBL LTDISSN: 1568-0266Frequency: 32 issues/year

CURRENT TOPICS IN MEDICINAL CHEMISTRY is a prestigious journal published by Bentham Science Publishers Ltd, dedicated to advancing the field of medicinal chemistry through the dissemination of high-quality research from 2001 to 2024. With an ISSN of 1568-0266 and an E-ISSN of 1873-4294, this journal is recognized for its significant contributions, as evidenced by its Scopus ranking in the 63rd percentile in the category of Drug Discovery, specifically at position #58 out of 157. Currently placed in Quartile 3 within Drug Discovery and Quartile 2 in miscellaneous medicine as of 2023, it serves as an essential resource for researchers, professionals, and students interested in the latest developments, methodologies, and applications in medicinal chemistry. The journal aims to foster collaboration and innovation by featuring original research articles, reviews, and brief communications that address current and emerging challenges in the discipline. Although it is not an open access platform, the journal's rich content is indispensable for those striving to enhance therapeutic strategies and drug development processes.

MINI-REVIEWS IN MEDICINAL CHEMISTRY

Exploring Innovations in Medicinal Chemistry.
Publisher: BENTHAM SCIENCE PUBL LTDISSN: 1389-5575Frequency: 20 issues/year

MINI-REVIEWS IN MEDICINAL CHEMISTRY is a distinguished journal published by Bentham Science Publishers, dedicated to the cutting-edge field of medicinal chemistry. With an ISSN of 1389-5575 and an E-ISSN of 1875-5607, this journal serves as an essential platform for researchers and professionals to disseminate concise yet comprehensive reviews that capture the latest advancements and trends in drug discovery, cancer research, pharmacology, and molecular medicine. Operating since 2001, it has consistently maintained a relevant presence in academia with its impressive rank metrics, including a Q2 category in Drug Discovery and Pharmacology in 2023, highlighting its significance in the scientific community. The journal is recognized for its rigorous peer-review process and provides an invaluable resource for students and researchers seeking insights into the rapidly evolving landscape of medicinal chemistry. With a commitment to excellence and innovation, MINI-REVIEWS IN MEDICINAL CHEMISTRY continues to foster knowledge exchange and inspire future breakthroughs in healthcare and therapeutic advancements.

Future Medicinal Chemistry

Transforming challenges into opportunities in drug development.
Publisher: Newlands Press LtdISSN: 1756-8919Frequency: 24 issues/year

Future Medicinal Chemistry is a premier journal dedicated to the rapidly evolving fields of drug discovery, pharmacology, and molecular medicine. Published by Newlands Press Ltd in the United Kingdom, this journal has garnered significant attention within the academic community, evidenced by its 2023 category rankings in Scopus, placing it in the Q2 quartile for Drug Discovery and the Q3 quartiles for both Molecular Medicine and Pharmacology. With an ISSN of 1756-8919 and an E-ISSN of 1756-8927, Future Medicinal Chemistry has been a cornerstone of scholarly discourse since its inception in 2009, continuously contributing to the advancement of knowledge and discussion in medicinal chemistry. The journal is committed to publishing high-quality, peer-reviewed research that addresses the challenges and innovations in drug development and therapeutic strategies, making it an essential resource for researchers, professionals, and students seeking to stay at the forefront of these critical fields. Engage with the latest findings and methodologies that shape the future of medicine by exploring the wealth of information offered within Future Medicinal Chemistry.

MOLECULAR DIVERSITY

Catalyzing Discoveries in Drug Development and Beyond
Publisher: SPRINGERISSN: 1381-1991Frequency: 4 issues/year

MOLECULAR DIVERSITY, published by Springer, stands as a pivotal platform within the fields of chemistry, biology, and pharmacology since its inception in 1995. This esteemed journal aims to foster interdisciplinary research and innovation, particularly in areas such as catalysis, drug discovery, inorganic and organic chemistry, and molecular biology. With a diverse scope that reflects contemporary scientific challenges, it has been recognized for its significant contributions, boasting commendable Scopus rankings and an impact factor that underscores its relevance in critical fields. Although not an open access journal, MOLECULAR DIVERSITY continues to influence and engage researchers, professionals, and students alike by providing a forum for high-quality peer-reviewed articles and cutting-edge research findings. As it converges years of scientific dynamism from 1995 to 2024, this journal remains vital for those advancing the frontiers of molecular science and engineering.

RUSSIAN JOURNAL OF BIOORGANIC CHEMISTRY

Pioneering Discoveries in Biochemistry and Organic Chemistry
Publisher: MAIK NAUKA/INTERPERIODICA/SPRINGERISSN: 1068-1620Frequency: 7 issues/year

Russian Journal of Bioorganic Chemistry (ISSN: 1068-1620, E-ISSN: 1608-330X), published by MAIK Nauka/Interperiodica/Springer, serves as a vital resource for researchers and professionals in the fields of bioorganic chemistry, biochemistry, and organic chemistry. With a focus on the integration of organic chemistry principles with biological processes, this journal aims to disseminate significant findings and advancements from both theoretical and practical perspectives. Although currently not open access, the journal retains a dedication to high-quality, peer-reviewed content, contributing to its reputation within the academic community. The 2023 Scopus rankings position it within the Q4 category for both biochemistry and organic chemistry, indicating its critical niche within these disciplines amid a competitive landscape. Since its inception in 1996, the journal has continued to evolve, providing enriching insights and fostering collaborations among scholars and practitioners alike, with publication converging up to the year 2024. By exploring complex biomolecular interactions and the synthesis of biologically relevant compounds, the Russian Journal of Bioorganic Chemistry remains a significant platform for advancing knowledge and innovation in the life sciences.

CHEMISTRY LETTERS

Shaping the future of chemistry, one letter at a time.
Publisher: CHEMICAL SOC JAPANISSN: 0366-7022Frequency: 12 issues/year

Chemistry Letters, published by the Chemical Society of Japan, is a distinguished academic journal that focuses on pivotal developments in the field of chemistry. Since its inception in 1973, the journal has been a vital platform for the dissemination of novel research findings across various sub-disciplines, encompassing both theoretical advancements and practical applications. As a testament to its significance in the community, Chemistry Letters has achieved a Category Quartile of Q2 in the 2023 ranking for miscellaneous Chemistry journals, reflecting its respected position among peers. Although it does not offer Open Access, the journal remains accessible through institutional subscriptions, thus ensuring a wide reach for its valuable content. With an active scope ranging from general chemistry topics to specialized studies, it is ideal for researchers, professionals, and students alike who seek to contribute to and expand their knowledge within this dynamic field. The journal continuously aims to promote excellence in chemical research, facilitating dialogue and collaboration among chemists worldwide.

BIOORGANIC & MEDICINAL CHEMISTRY

Innovating Drug Discovery Through Chemistry
Publisher: PERGAMON-ELSEVIER SCIENCE LTDISSN: 0968-0896Frequency: 24 issues/year

BIOORGANIC & MEDICINAL CHEMISTRY, published by Pergamon-Elsevier Science Ltd, is a prominent journal in the fields of biochemical research and drug discovery, with an ISSN of 0968-0896 and an E-ISSN of 1464-3391. Established in 1993, it has garnered respect and recognition, evidenced by its categorization in various quartile ranks across 2023, including Q2 in Clinical Biochemistry and Pharmaceutical Science. It holds significant Scopus rankings, placing it in the 75th percentile in Pharmaceutical Science and 74th percentile in Organic Chemistry, highlighting its influential contributions to ongoing research and developments. This journal provides a platform for disseminating advancements in bioorganic and medicinal chemistry, focusing on innovative methodologies, therapeutic advancements, and molecular pharmacology. Although it does not follow an open-access model, it remains a key resource for researchers, professionals, and students aiming to stay at the forefront of scientific discovery in the UK and beyond. The journal’s commitment to enhancing knowledge within the biomedical community makes it an essential read for those passionate about this dynamic field.

ChemMedChem

Innovating drug discovery through interdisciplinary collaboration.
Publisher: WILEY-V C H VERLAG GMBHISSN: 1860-7179Frequency: 24 issues/year

ChemMedChem is a leading international journal published by WILEY-V C H VERLAG GMBH in the United Kingdom, specializing in the interdisciplinary fields of medicinal chemistry and drug discovery. With a commendable impact factor that places it in the Q1 quartile for Organic Chemistry and among the Q2 ranks in several other key categories including Biochemistry, Molecular Medicine, and Pharmacology, ChemMedChem serves as a vital platform for the dissemination of innovative research and transformative insights in the development of pharmaceutical agents. Since its inception in 2006, this journal has been at the forefront of advancing knowledge that bridges the gap between fundamental research and practical applications in medicine, making it an essential resource for researchers, professionals, and students alike. Although it currently does not offer Open Access options, the journal ensures high-quality peer-reviewed content that engages its audience and fosters collaborative scientific discourse.

ACS Medicinal Chemistry Letters

Elevating medicinal chemistry with every groundbreaking letter.
Publisher: AMER CHEMICAL SOCISSN: 1948-5875Frequency: 12 issues/year

ACS Medicinal Chemistry Letters, published by the American Chemical Society, is a distinguished journal dedicated to advancing the field of medicinal chemistry. With impressive rankings in the 2023 category quartiles—Q1 in Drug Discovery and Organic Chemistry as well as Q2 in Biochemistry—this journal serves as a vital platform for researchers seeking to publish innovative findings and methodologies in drug development and therapeutic advancements. The journal's notable impact is reflected in its Scopus rankings, where it stands at #43 in Organic Chemistry and #45 in Drug Discovery. Although it does not currently offer open access, the contributions published from 2010 to 2024 provide a wealth of knowledge critical to both academia and industry. As a key resource for students, professionals, and researchers in the fields of chemistry and pharmacology, ACS Medicinal Chemistry Letters plays an essential role in shaping the future of medicinal therapeutics.

CURRENT DRUG TARGETS

Navigating the Landscape of Pharmacology
Publisher: BENTHAM SCIENCE PUBL LTDISSN: 1389-4501Frequency: 16 issues/year

CURRENT DRUG TARGETS is a leading peer-reviewed journal dedicated to advancements in the fields of Clinical Biochemistry, Drug Discovery, Molecular Medicine, and Pharmacology. Published by Bentham Science Publishers Ltd, this esteemed journal has solidified its position in the academic community with a 2023 Q2 ranking in several categories, highlighting its influence and relevance in drug research and development. With an ISSN of 1389-4501 and E-ISSN 1873-5592, CURRENT DRUG TARGETS facilitates the dissemination of high-quality articles that explore novel therapeutic strategies and drug design principles. Catered to researchers, professionals, and students, the journal has a commitment to advancing knowledge while addressing contemporary challenges in pharmacological sciences. As it converges from 2000 to 2024, CURRENT DRUG TARGETS remains a vital resource in understanding the complexities of drug action and interaction, making it indispensable for anyone pursuing cutting-edge research in related disciplines.